Country: Armenía
Tungumál: enska
Heimild: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
celecoxib
Apotex Inc.
M01AH01
celecoxib
200mg
capsules
(100) in plastic container
Prescription
Registered
2017-12-08
IMPORTANT: PLEASE READ _APO-CELECOXIB Product Monograph _ Page 46 of 49 PART III: CONSUMER INFORMATION APO-CELECOXIB CELECOXIB CAPSULES READ THIS INFORMATION EACH TIME YOU REFILL YOUR PRESCRIPTION IN CASE NEW INFORMATION HAS BEEN ADDED. THIS LEAFLET IS A SUMMARY DESIGNED SPECIFICALLY FOR YOU TO READ. IT WILL NOT TELL YOU EVERYTHING ABOUT APO-CELECOXIB. See your health care provider and pharmacist regularly and ask them questions about your health and any medications you take. ABOUT THIS MEDICATION WHAT THE MEDICATION IS USED FOR: Your health care provider has prescribed APO- CELECOXIB for you for one or more of the following medical conditions: Osteoarthritis – relieve pain Rheumatoid Arthritis – relieve joint pain and swelling Ankylosing Spondylitis – relieve pain Sprains, After orthopaedic (bone and joint) surgery (NOT open heart surgery), dental extraction – to relieve short-term pain (maximum use of 7 days) WHAT IT DOES: APO-CELECOXIB (celecoxib), as a nonsteroidal anti- inflammatory drug (NSAID), can reduce the type of prostaglandins (chemicals), produced by your body which cause joint swelling, redness and pain. At prescribed doses, APO-CELECOXIB does not affect the type of prostaglandins that helps maintain the protective layer of the stomach, and reduces the chances of bleeding from the stomach. APO-CELECOXIB, as a nonsteroidal anti- inflammatory drug (NSAID), does NOT cure your illness or prevent it from getting worse. APO- CELECOXIB can only relieve pain and reduce swelling as long as you continue to take it. WHEN IT SHOULD NOT BE USED: DO NOT TAKE APO-CELECOXIB IF YOU HAVE ANY OF THE FOLLOWING MEDICAL CONDITIONS: HEART BYPASS SURGERY (PLANNING TO HAVE OR RECENTLY HAD) SEVERE, UNCONTROLLED HEART FAILURE ALLERGY TO CELECOXIB OR ANY OF THE OTHER INGREDIENTS IN APO-CELECOXIB ALLERGY TO SULFONAMIDE DRUGS ALLERGY TO ASA (ACETYLSALICYLIC ACID) OR OTHER NSAIDS (NONSTEROIDAL ANTI- INFLAMMATORY DRUGS) CURRENT PREGNANCY (AFTER 28 WEEKS OF PREGNANCY) CURRENTLY BR Lestu allt skjalið
_APO-CELECOXIB Product Monograph_ Page 1 of 49 PRODUCT MONOGRAPH APO-CELECOXIB CELECOXIB CAPSULES 100 MG AND 200 MG NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) APOTEX INC. DATE OF REVISION: 150 SIGNET DRIVE MARCH 21, 2016 TORONTO ONTARIO M9L 1T9 CONTROL NO.: 189166 _APO-CELECOXIB Product Monograph_ Page 2 of 49 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .............................................................. 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS ....................................................................................................... 4 WARNINGS AND PRECAUTIONS ....................................................................................... 4 ADVERSE REACTIONS .....................................................................................................13 DRUG INTERACTIONS ......................................................................................................20 DOSAGE AND ADMINISTRATION .....................................................................................23 OVERDOSAGE ...................................................................................................................24 ACTION AND CLINICAL PHARMACOLOGY ......................................................................25 STORAGE AND STABILITY................................................................................................27 DOSAGE FORMS, COMPOSITION AND PACKAGING ......................................................27 PART II: SCIENTIFIC INFORMATION ...................................................................................28 PHARMACEUTICAL INFORMATION ..................................................................................28 CLINICAL TRIALS ........................................................................................ Lestu allt skjalið